Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

INTERCEPT PHARMACEUTICALS INC

Form 4

November 12, 2015 EODM 4

FORM	Ι Δ							OIVIB AP	PROVAL	
_	UNITED	STATES SECU Wa	RITIES A ashington			NGE C	OMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1 Section 17(a) of the Public Utility Holding Company Act of 1							e Act of 1934,	burden hours per response 0.5		
may conto See Instr 1(b).		30(h) of the I	nvestment	: Compar	ıy Ac	et of 1940	0			
(Print or Type l	Responses)									
1. Name and A Shapiro Dav	er Name and			6	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) C/O INTER PHARMAC W. 15TH S'	MACEUT of Earliest T (Day/Year) 2015		inc	-	Director 10% Owner Symbol Street, which is a second control of the control of th					
	nendment, Day/Yea		1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
	K, NY 10011	7.)					Person			
(City)	(State)	(Zip) Tal	ble I - Non-I	Derivative	Secui	rities Acqu	iired, Disposed of,	or Beneficiall	-	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code (Instr. 8)	4. Securi on(A) or Di (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/10/2015		M(1)	3,500	A	\$ 8.6667	32,659	D		
Common Stock	11/10/2015		S(1)	3,500	D	\$ 204.15	29,159	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

OMB APPROVAL

Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 8.6667	11/10/2015		M <u>(1)</u>		3,500	(2)	08/16/2020	Common Stock	3,500

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Shapiro David C/O INTERCEPT PHARMACEUTICALS, INC. 450 W. 15TH STREET, SUITE 505 NEW YORK, NY 10011

CMO and EVP - Development

Signatures

/s/ Bryan Yoon, as attorney-in-fact 11/12/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2014.
- (2) All shares underlying this option have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2